A randomized, 48-week, placebocontrolled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study

被引:205
作者
Hoeger, KM
Kochman, L
Wixom, N
Craig, K
Miller, RK
Guzick, DS
机构
[1] Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Nursing, Rochester, NY 14627 USA
关键词
polycystic ovary syndrome; obesity; ovulation;
D O I
10.1016/j.fertnstert.2004.02.104
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To obtain data from a pilot randomized trial on the effect of metformin therapy and lifestyle modification on ovulation and androgen concentrations in women with polycystic ovary syndrome (PCOS). Design: Prospective, randomized, placebo-controlled pilot trial. Setting: Academic medical center. Patient(s): Thirty-eight overweight or obese women with PCOS. Intervention(s): All subjects were randomized to one of four 48-week interventions: metformin 850 mg two times per day, lifestyle modification plus metformin 850 mg two times per day, lifestyle modification plus placebo, or placebo alone. Main Outcome Measure(s): Recruitment, dropout, and compliance with a long-term lifestyle intervention in PCOS; preliminary estimates of treatment effect on ovulation, as measured by weekly urinary pregnanediol glucuronide, and on total T and free androgen index. Result(s): It was necessary to screen seven women to have one subject randomized. The dropout rate was 39%, with the majority of dropouts occurring within the first 24 weeks. Mean body mass index was >39 mg/kg(2). Modest weight reduction was found in all treatment groups, with the most significant reduction occurring with the combination of metformin and lifestyle intervention. Significant androgen reduction occurred in the combination group only. Ovulation rates did not differ significantly between groups. However, when data were analyzed by presence or absence of weight reduction in subjects, independent of treatment group, the estimated odds ratio for weight loss was 9.0 (95% confidence interval 1.2-64.7) with respect to regular ovulation. If weight loss occurred during metformin therapy, the odds ratio for regular ovulation was 16.2 (95% confidence interval 4.4-60.2). Conclusion(s): Key methodologic issues for a large-scale, randomized trial of lifestyle intervention in PCOS include minimizing early dropout from the lifestyle intervention and including a range of body mass index that is not skewed toward severe obesity. Weight reduction might play the most significant role in restoration of ovulation in obese women with PCOS.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 36 条
[1]  
Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083
[2]   Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial [J].
Azziz, R ;
Ehrmann, D ;
Legro, RS ;
Whitcomb, RW ;
Hanley, R ;
Fereshetian, AG ;
O'Keefe, M ;
Ghazzi, MN .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04) :1626-1632
[3]  
BARBIERI RL, 1994, J REPROD MED, V39, P327
[4]   INSULIN RESISTANCE IN NON-OBESE PATIENTS WITH POLYCYSTIC OVARIAN DISEASE [J].
CHANG, RJ ;
NAKAMURA, RM ;
JUDD, HL ;
KAPLAN, SA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 57 (02) :356-359
[5]   PROFOUND PERIPHERAL INSULIN RESISTANCE, INDEPENDENT OF OBESITY, IN POLYCYSTIC OVARY SYNDROME [J].
DUNAIF, A ;
SEGAL, KR ;
FUTTERWEIT, W ;
DOBRJANSKY, A .
DIABETES, 1989, 38 (09) :1165-1174
[6]   Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis [J].
Dunaif, A .
ENDOCRINE REVIEWS, 1997, 18 (06) :774-800
[7]   The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome [J].
Dunaif, A ;
Scott, D ;
Finegood, D ;
Quintana, B ;
Whitcomb, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (09) :3299-3306
[8]   CHARACTERIZATION OF GROUPS OF HYPERANDROGENIC WOMEN WITH ACANTHOSIS NIGRICANS, IMPAIRED GLUCOSE-TOLERANCE, AND - OR HYPERINSULINEMIA [J].
DUNAIF, A ;
GRAF, M ;
MANDELI, J ;
LAUMAS, V ;
DOBRJANSKY, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 65 (03) :499-507
[9]   Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome [J].
Ehrmann, DA ;
Cavaghan, MK ;
Imperial, J ;
Sturis, J ;
Rosenfield, RL ;
Polonsky, KS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :524-530
[10]   Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome [J].
Ehrmann, DA ;
Schneider, DJ ;
Sobel, BE ;
Cavaghan, MK ;
Imperial, J ;
Rosenfield, RL ;
Polonsky, KS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (07) :2108-2116